Treatment options for severe sepsis and septic shock
- PMID: 16771617
- DOI: 10.1586/14787210.4.3.395
Treatment options for severe sepsis and septic shock
Abstract
Despite significant advances in the understanding of the pathophysiology of sepsis, severe sepsis and septic shock continue to be associated with high morbidity and mortality. Eradication of infection, with appropriate antibiotics and source control, remains the cornerstone of sepsis management, but does not ensure survival. Aggressive supportive care, such as fluid resuscitation, vasoactive agents or mechanical ventilation, is often required. With the exception of drotrecogin alfa, attempts to modulate the inflammatory response in sepsis have generally been unsuccessful. Early goal-directed therapy targeting adequate central venous oxygen saturation appears to improve outcome. Recently, there has been renewed interest in the use of corticosteroids, not as anti-inflammatory agents, but as replacement therapy. There is also some evidence to suggest that tight glucose control may improve outcome in these patients.
Similar articles
-
Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.Acad Emerg Med. 2006 Jan;13(1):109-13. doi: 10.1197/j.aem.2005.08.005. Epub 2005 Dec 19. Acad Emerg Med. 2006. PMID: 16365336
-
Pharmacological treatment of sepsis.Fundam Clin Pharmacol. 2008 Aug;22(4):355-61. doi: 10.1111/j.1472-8206.2008.00606.x. Fundam Clin Pharmacol. 2008. PMID: 18705746 Review.
-
Optimum treatment of severe sepsis and septic shock: evidence in support of the recommendations.Dis Mon. 2004 Apr;50(4):168-213. doi: 10.1016/j.disamonth.2003.12.003. Dis Mon. 2004. PMID: 15133467 Review.
-
The definition of septic shock: implications for treatment.Crit Care Resusc. 2007 Mar;9(1):101-3. Crit Care Resusc. 2007. PMID: 17352674
-
The current management of septic shock.Minerva Med. 2008 Oct;99(5):431-58. Minerva Med. 2008. PMID: 18971911 Review.
Cited by
-
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.Crit Care. 2012 Feb 17;16(1):R31. doi: 10.1186/cc11203. Crit Care. 2012. PMID: 22340283 Free PMC article. Clinical Trial.
-
Matrix metalloproteinases as drug targets in infections caused by gram-negative bacteria and in septic shock.Clin Microbiol Rev. 2009 Apr;22(2):224-39, Table of Contents. doi: 10.1128/CMR.00047-08. Clin Microbiol Rev. 2009. PMID: 19366913 Free PMC article. Review.
-
Mediatory roles of leukotriene B4 receptors in LPS-induced endotoxic shock.Sci Rep. 2019 Apr 11;9(1):5936. doi: 10.1038/s41598-019-42410-8. Sci Rep. 2019. PMID: 30976041 Free PMC article.
-
Complement and sepsis-induced heart dysfunction.Mol Immunol. 2017 Apr;84:57-64. doi: 10.1016/j.molimm.2016.11.012. Epub 2016 Dec 5. Mol Immunol. 2017. PMID: 27931779 Free PMC article. Review.
-
Whey Acidic Protein/Four-Disulfide Core Domain 21 Regulate Sepsis Pathogenesis in a Mouse Model and a Macrophage Cell Line via the Stat3/Toll-Like Receptor 4 (TLR4) Signaling Pathway.Med Sci Monit. 2018 Jun 14;24:4054-4063. doi: 10.12659/MSM.907176. Med Sci Monit. 2018. PMID: 29900929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical